Ayana awarded $300K to study benefits of saffron in Huntington’s

Living with Huntington’s disease is a roller coaster life

Lauren holds a Huntington’s Disease Association banner at the Big Half London, a half-marathon. (Photos courtesy of Lauren) This is Lauren’s story: Inexplicably, Dad kept us away from Nan, who spent years in a care home. Eventually, Dad tested positive for Huntington’s disease (HD). After meeting my future…

FDA approves Ingrezza Sprinkle to treat chorea in Huntington’s

The U.S. Food and Drug Administration (FDA) has approved Neurocrine Biosciences’ oral granules formulation of Ingrezza (valbenazine) — called Ingrezza Sprinkle — for treating chorea, or involuntary movements, in adults with Huntington’s disease. The new formulation, taken once per day, is designed to provide an easier administration option…

The trauma of Huntington’s disease is shared by the family

Jennifer Ushe’s grandparents, Jean and Edward Moshier. (Photo courtesy of Jennifer Ushe) This is Jennifer Ushe’s family story: Both of my grandparents died 10 years before I was born: Grandpa, unexpectedly and tragically, of a heart attack, and Grandma, expectedly but no less tragically, of Huntington’s disease. My…

This awareness month, spotlight is on the patient experience

May is Huntington’s Disease Awareness Month, and this year the focus is on the patient experience. Huntington’s disease (HD) is a neurodegenerative disorder thought to affect 4.9 per 100,000 people worldwide, including about 41,000 U.S. residents, and can impact many aspects of everyday life. While each patient’s journey…

AAN 2024: Ingrezza eases chorea, regardless of antipsychotics use

Daily treatment with Ingrezza (valbenazine) led to sustained reductions in chorea — characterized by involuntary, unpredictable body movements — for nine months among the small group of Huntington’s disease patients simultaneously using antipsychotic medications in the Phase 3 KINECT-HD2 trial. In addition, improvements in chorea were also…